Teriparatide


Recombinant PTH 1-34 anabolic bone agent

Recombinant parathyroid hormone fragment 1-34; the first true anabolic agent for osteoporosis.

Abstract

Teriparatide (parathyroid hormone (1-34) recombinant; CAS 52232-67-4; 34-amino-acid peptide; molecular weight approximately 4117 Da) is a recombinant fragment of human parathyroid hormone (the biologically active N-terminal portion), approved by the FDA in 2002 (Forteo). Mechanism is paradoxical: chronic continuous high PTH (as in hyperparathyroidism) drives net bone resorption via osteoclast activation, but pulsatile once-daily PTH 1-34 administration drives net bone formation via direct osteoblast activation and reduced osteoblast apoptosis. The mechanism explanation involves PTH receptor-G protein signaling kinetics that favor osteoblast over osteoclast effects under intermittent stimulation. Plasma half-life is approximately 1 hour. Approved for severe osteoporosis with high fracture risk. The 2-year cumulative-dose limitation reflects an osteosarcoma signal observed in rat carcinogenicity studies (subsequently not reproduced in humans). Used as the canonical anabolic bone agent in osteoporosis research.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph